

References

1-**Daniels ME.** "Lilly's Humatrope Experience". *Nature Biotechnology* (1992)10: 812.

2- **Conceicao F.L., Bojensen A., Lunde Jorgensen J.O., Christiansen J.S.** Growth hormone therapy in adults. *Frontiers in Neuroendocrinology* (2001)Volume 22 (3): pages 213-246.

3-**Gardner, David G., Shoback, Dolores.** *Greenspan's Basic and Clinical Endocrinology* 8th ed.(2007) pp. 193-201

4- **Derek Le Roith, Carolyn Bondy, Shoshana Yakar, Jun-Li Liu and Andrew Butler.** The Somatomedin Hypothesis *Endocrine Reviews* (2001) 22 (1): 53-74

5- **Stephen B Trippel, Richard D Coutts, Thomas A Einhorn, et al.** Instructional Course Lectures, The American Academy of Orthopaedic Surgeons - Growth Factors as Therapeutic Agents. *The Journal of Bone and Joint Surgery (American)*.(1996) 78:1272-86.

6- **Jay R Lieberman MD, Aaron Daluiski MD and Thomas A Einhorn MD.** The Role of Growth Factors in the Repair of Bone,

Biology and Clinical Applications. The Journal of Bone and Joint Surgery (American). (2002) 84:1032-1044.

7-**King M W, Ph D, I U School of medicine.** Growth factors and cytokines , medical biochemistry,miking at iupui.edu. (2008)

8- **M F Termaat, F C Den Boer, F C Bakker, et al.** Bone Morphogenetic Proteins. Development and Clinical Efficacy in the Treatment of Fractures and Bone Defects. The Journal of Bone and Joint Surgery (American). (2005) 87:1367-1378.

9- **Groeneveld EH, Burger EH.** Bone morphogenetic proteins in human bone regeneration. Eur J Endocrinol. (2000) 142:9-21.

10- **Rosanna Dono** Fibroblast growth factors as regulators of central nervous system development and function Am J Physiol Regul Integr Comp Physiol (2003) 284: R867-R881.

11-**Sofroniew MV, Howe CL, Mobley WC.** Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci. (2001) 24:1217-81.

12-**Claes Ohlsson, Bengt-Åke Bengtsson, Olle G. P. Isaksson, Troels T. Andreassen and Maria C. Słotweg** “Growth Hormone and Bone” Endocrine Reviews (1998) 19 (1): 55-79

13- **Douglas J. DiGirolamo, Aditi Mukherjee, Keertik Fulzele, Yujun Gan, Xuemei Cao, Stuart J. Frank, and Thomas L. Clemens** · Mode of Growth Hormone Action in Osteoblasts *J. Biol. Chem.*, (2007) Vol. 282, Issue 43, 31666-31674

14- **Michael Raschke, Michael Højby Rasmussen¹, Shunmugam Govender², David Segal³, Mette Suntum¹ and Jens Sandahl Christiansen** “Effects of growth hormone in patients with tibial fracture: a randomised, double-blind, placebo-controlled clinical trial” *European Journal of Endocrinology* (2007) 156 341–351

15- **Barnes GL, Kostenuik PJ, Gerstenfeld LC, Einhorn TA.** Growth factor regulation of fracture repair. *J Bone Miner Res.* (1999) 14: 1805-15.

16- **Massague J.** TGFbeta signaling: receptors, transducers, and MAD proteins. *Cell.* (1996) 85:947-50.

17- **Heldin CH, Miyazono K, ten Dijke P.** TGF-beta signalling from cell membrane to nucleus through SMAD proteins. *Nature.* (1997) 390:465-71.

18- **Kawabata M, Imamura T, Miyazono K.** Signal transduction by bone morphogenetic proteins. *Cytokine Growth Factor Rev.* (1998) 9:49-61.

- 19- **Schmitt JM, Hwang K, Winn SR, Hollinger JO.** Bone morphogenetic proteins: an update on basic biology and clinical relevance. *J Orthop Res.* (1999) 17: 269-78.
- 20- **Groeneveld EH, Burger EH.** Bone morphogenetic proteins in human bone regeneration. *Eur J Endocrinol.* (2000) 142:9-21.
- 21- **Cheng H, Jiang W, Phillips FM, et al.** Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). *J Bone Joint Surg Am.* (2003) 85:1544-52.
- 22- **M F Termaat, F C Den Boer, F C Bakker, et al.** Bone Morphogenetic Proteins. Development and Clinical Efficacy in the Treatment of Fractures and Bone Defects. *The Journal of Bone and Joint Surgery (American).* (2005) 87:1367-1378.
- 23- **Weber FE, Eyrich G, Gratz KW, et al.** Disulfide bridge conformers of mature BMP are inhibitors for heterotopic ossification. *Biochem Biophys Res Commun.* (2001) 286:554-8.
- 24- **Zwijnsen A, Verschueren K, Huylebroeck D.** New intracellular components of bone morphogenetic protein/Smad signaling cascades. *FEBS Lett.* (2003) 546:133-9.

- 25- **Balemans W, Van Hul W.** Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. *Dev Biol.* (2002) 250:231-50.
- 26- **Canalis E, Economides AN, Gaggero E.** Bone morphogenetic proteins, their antagonists, and the skeleton. *Endocr Rev.* (2003) 24:218-35.
- 27- **Valentin-Opran A, Wozney J, Csimma C, et al.** Clinical evaluation of recombinant human bone morphogenetic protein-2. *Clin Orthop Relat Res.* (2002) 395:110-20.
- 28- **Udagawa N.** Mechanisms involved in bone resorption. *Biogerontology.* (2002) 3:79-83.
- 29- **Lind M.** Growth factor stimulation of bone healing. Effects on osteoblasts, osteomies, and implants fixation. *Acta Orthop Scand Suppl.* (1998) 283:2-37.
- 30- **Xu X, Weinstein M, Li C, Deng C.** Fibroblast growth factor receptors (FGFRs) and their roles in limb development. *Cell Tissue Res.* (1999) 296:33-43.
- 31- **Dietz F, Muschler GF.** Update on the genetic basis of disorders with orthopaedic manifestations. In: Buckwalter JA, Einhorn TA, Simon S, editors. *Orthopaedic basic science.*

Rosemont, IL: American Academy of Orthopaedic Surgeons.
(2000) p 114.

32-**Radomsky ML, Thompson AY, Spiro RC, Poser JW.** Potential role of fibroblast growth factor in enhancement of fracture healing. Clin Orthop. (1998) 355 Suppl: S283-93.

33- **Yu H, Rohan T.** Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst (2000) 92:1472-89.

34-**Jones JI, Clemmons DR.** Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev (1995) 16:3-34.

35-**Oldham S, Hafen E.** Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control. Trends Cell Biol (2003) 13:79-85.

36- **Firth SM, Baxter RC.** Cellular actions of the insulin-like growth factor binding proteins. Endocrine Reviews (2002) 23:824-54.

37- **Rajaram S, Baylink DJ, Mohan S.** Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev (1997) 18:801-31.

38-**Yu JC, Li W, Wang LM, et al.** Differential requirement of a motif within the carboxyl-terminal domain of alpha-platelet-derived growth factor (alpha PDGF) receptor for PDGF focus forming activity chemotaxis, or growth. *J. Biol. Chem.* (1995) 270 (13): 7033–6.

39-**Eugenia Karamoysoyli, Rebecca C. Burnand, David R. Tomlinson and Natalie J. Gardiner** Neurtin Mediates Nerve Growth Factor–Induced Axonal Regeneration and Is Deficient in Experimental Diabetic Neuropathy. *Diabetes* 57:181-189, (2008)

40-**Linkhart TA, Mohan S, Baylink DJ.** Growth factors for bone growth and repair: IGF, TGF beta and BMP. *Bone.* (1996) 19 (1 Suppl):1S-12S.

41- **Lind M, Schumacker B, Soballe K, et al.** Transforming growth factor-beta enhances fracture healing in rabbit tibiae. *Acta Orthop Scand.* (1993) 64:553-6.

42- **Nielsen HM, Andreassen TT, Ledet T, Oxlund H.** Local injection of TGF-beta increases the strength of tibial fractures in the rat. *Acta Orthop Scand.*(1994) 65:37-41.

43- **Critchlow MA, Bland YS, Ashhurst DE.** The effect of exogenous transforming growth factor-beta 2 on healing fractures in the rabbit. *Bone.* (1995) 16:521-7.

- 44- **Dudley AT, Lyons KM, Robertson EJ.** A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. *Genes Dev.* (1995) 9:2795-807.
- 45- **Wozney JM, Rosen V, Celeste AJ, et al.** Novel regulators of bone formation: molecular clones and activities. *Science.* (1988) 242:1528-34.
- 46- **Cook SD, Wolfe MW, Salkeld SL, Rueger DC.** Effect of recombinant human osteogenic protein-1 on healing of segmental defects in non-human primates. *J Bone Joint Surg Am.* (1995) 77:734-50.
- 47- **Sciadini MF, Johnson KD.** Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model. *J Orthop Res.* (2000) 18:289-302.
- 48- **Bostrom MP, Camacho NP.** Potential role of bone morphogenetic proteins in fracture healing. *Clin Orthop.* (1998) 355 Suppl: S274-82.
- 49- **Sandhu HS, Kanim LE, Kabo JM, et al.** Evaluation of rhBMP-2 with an OPLA carrier in a canine posterolateral (transverse process) spinal fusion model. *Spine.* (1995) 20:2669-82.

50- **Boden SD, Martin GJ Jr, Horton WC, et al.** Laparoscopic anterior spinal arthrodesis with rhBMP-2 in a titanium interbody threaded cage. *J Spinal Disord.* (1998) 11:95-101.

51- **Kato T, Kawaguchi H, Hanada K, et al.** Single local injection of recombinant fibroblast growth factor-2 stimulates healing of segmental bone defects in rabbits. *J Orthop Res.* (1998) 16:654-9.

52- **Nakamura T, Hara Y, Tagawa M, et al.** Recombinant human basic fibroblast growth factor accelerates fracture healing by enhancing callus remodeling in experimental dog tibial fracture. *J Bone Miner Res.* (1998) 13:942-9.

53- **Radomsky ML, Aufdemorte TB, Swain LD, et al.** Novel formulation of fibroblast growth factor-2 in a hyaluronan gel accelerates fracture healing in nonhuman primates. *J Orthop Res.* (1999) 17:607-14.

54- **Bak B, Jorgensen PH, Andreassen TT.** Dose response of growth hormone on fracture healing in the rat. *Acta Orthop Scand.* (1990) 61:54-7.

55- **Carpenter JE, Hipp JA, Gerhart TN, et al.** Failure of growth hormone to alter the biomechanics of fracture-healing in a rabbit model. *J Bone Joint Surg Am.* (1992) 74:359-67.

56- **Thaller SR, Dart A, Tesluk H.** The effects of insulin-like growth factor-1 on critical-size calvarial defects in Sprague-Dawley rats. *Ann Plast Surg.* (1993) 31:429-33.

57- **Andrew JG, Hoyland JA, Freemont AJ, Marsh DR.** Platelet-derived growth factor expression in normally healing human fractures. *Bone.* (1995) 16:455-60.

58- **Nash TJ, Howlett CR, Martin C, et al.** Effect of platelet-derived growth factor on tibial osteotomies in rabbits. *Bone.* (1994) 5:203-8.

59- **Scott A Rodeo, Hollis G Potter, Sumito Kawamura, et al.** Biologic Augmentation of Rotator Cuff Tendon-Healing with Use of a Mixture of Osteoinductive Growth Factors. *The Journal of Bone and Joint Surgery (American).* (2007) 89:2485-2497.

60- **Chan KC, Burkhart SS, Thiagarajan P, Goh JC.** Optimization of stacked half-hitch knots for arthroscopic surgery. *Arthroscopy.* (2001) 17:752 -9.

61- **Anderson K, Seneviratne AM, Izawa K, et al.** Augmentation of tendon healing in an intraarticular bone tunnel with use of a bone growth factor. *Am J Sports Med.* (2001) 29:689 -98.

62- **Lieberman JR, Daluiski A, Stevenson S, et al.** The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. *J Bone Joint Surg Am.* (1999) 81:905-17.

63- **Ladd AL, Pliam NB.** Use of bone-graft substitutes in distal radius fractures. *J Am Acad Orthop Surg.* (1999) 7:279-90.

64- **Boden SD, Zdeblick TA, Sandhu HS, Heim SE.** The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. *Spine.* (2000) 25:376-81.

65- **Winn SR, Uludag H, Hollinger JO.** Carrier systems for bone morphogenetic proteins. *Clin Orthop.* (1999) 367 Suppl: S95-106.

66- **Johnson EE, Urist MR, Finerman GA.** Resistant nonunions and partial or complete segmental defects of long bones. Treatment with implants of a composite of human bone morphogenetic protein (BMP) and autolyzed, antigen-extracted, allogeneic (AAA) bone. *Clin Orthop.* (1992) 277:229-37.

67- **Behravesh E, Yasko AW, Engel PS, Mikos AG.** Synthetic biodegradable polymers for orthopaedic applications. *Clin Orthop.* (1999) 367 Suppl: S118-29.

68-**Uludag H, Gao T, Porter TJ, et al.** Delivery systems for BMPs: factors contributing to protein retention at an application site. *J Bone Joint Surg Am.* (2001) 83 Suppl 1:S128-35.

69-**Johnson KD, Frierson KE, Keller TS, et al.** Porous ceramics as bone graft substitutes in long bone defects: a biomechanical, histological, and radiographic analysis. *J Orthop Res.* (1996) 14:351-69.

70-**Solchaga LA, Dennis JE, Goldberg VM, Caplan AI.** Hyaluronic acid-based polymers as cell carriers for tissue-engineered repair of bone and cartilage. *J Orthop Res.* (1999) 17:205-13.

71-**Evans CH, Robbins PD.** Possible orthopaedic applications of gene therapy. *J Bone Joint Surg Am.* (1995) 77:1103-14.

72-**Scaduto AA, Lieberman JR.** Gene therapy for osteoinduction. *Orthop Clin North Am.* (1999) 30:625-33.

73-**Kay MA, Glorioso JC, Naldini L.** Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. *Nat Med.* (2001) 7:33-40.

74-**Viggeswarapu M, Boden SD, Liu Y, et al.** Adenoviral delivery of LIM mineralization protein-1 induces new-bone

formation in vitro and in vivo. *J Bone Joint Surg Am.* (2001) 83:364-76.

75-Praemer A, Furner S, Rice DP. Musculoskeletal conditions in the United States. Park Ridge, IL: American Academy of Orthopaedic Surgeons; (1992).

76-Younger EM, Chapman MW. Morbidity at bone graft donor sites. *J Orthop Trauma.* (1989) 3:192-5.

77-Friedlaender GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. *J Bone Joint Surg Am.* (2001) 83 Suppl 1:S151-8.

78-Bouxsein ML, Turek TJ, Blake CA, D'Augusta D, Li X, Stevens M, Seeherman HJ, Wozney JM. Recombinant human bone morphogenetic protein-2 accelerates healing in a rabbit ulnar osteotomy model. *J Bone Joint Surg Am,* (2001) 83: 1219-30.

79-Li RH, Wozney JM. Delivering on the promise of bone morphogenetic proteins. *Trends Biotechnol,* (2001) 19: 255-65.

80-Blokhuis TJ, den Boer FC, Bramer JA, Jenner JM, Bakker FC, Patka P, Haarman HJ. Biomechanical and histological aspects of fracture healing, stimulated with osteogenic protein-1. *Biomaterials,* (2001) 22: 725-30.

81-**Thomas A. Einhorn, MD, Robert J Majeska, PhD, Ahamed Mohaideen, MD, Eric M. Kagel, MD, Mary L. Bouxsein, PhD, Thomas J. Turek and John M. Wozney, PhD** A Single Percutaneous Injection of Recombinant Human Bone Morphogenetic Protein-2 Accelerates Fracture Repair *The Journal of Bone and Joint Surgery (American)* (2003) 85:1425-1435

82- **Deutsche Banc.** Alex Brown. Estimates and Company Information. February (2001).

83- **Burkus JK, Dorchak JD, Sanders DL.** Radiographic assessment of interbody fusion using recombinant human bone morphogenetic protein type 2. *Spine.* (2003) 28:372-7.

84- **Michael Raschke, Michael Højby Rasmussen, Shunmugam Govender, David Segal, Mette Suntum** Effects of growth hormone in patients with tibial fracture: a randomised, double-blind, placebo-controlled clinical trial *European Journal of Endocrinology*, (2007) Vol 156, Issue 3, 341-351